VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

May, 18 2022

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be available for one-on-one meetings with investors. HC Wainwright & Co. Global Investment Conference – Presentation Details Date: Wednesday, May 25, 2022 Time: 9:00 a.m. ET Webcast Link: https://journey.ct.events/view/f49ba6f9-4835-4fb5-9a1c-0c341c71da26 *a replay will be…

Read More

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May, 12 2022

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th   BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the quarter ended March 31, 2022 and provided a business update. “VYNE made significant progress in the first quarter of 2022 with our pipeline of novel programs…

Read More